Rallybio Corporation filed an 8-K on November 10, 2026, announcing that its board, with Avenzo Therapeutics' mutual agreement, approved a 1-for-2 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on November 20, 2026, in connection with the planned merger with Avenzo Therapeutics, Inc.
Key Highlights
- Split ratio set at 1-for-2: Rallybio's Board of Directors, with Avenzo's mutual agreement, approved the specific ratio on November 8, 2026, from a range of 1-for-2 to 1-for-9 that stockholders had authorized at the Annual Meeting on November 4, 2026.
- Share count reduced: Outstanding shares are expected to decrease from approximately 5.6 million to approximately 2.8 million, prior to the closing of the merger.
- Effective date: The reverse stock split is expected to become effective at 12:01 a.m., Eastern Time, on November 20, 2026.
- Name and ticker change planned: Following the merger closing and applicable Nasdaq approvals, the company plans to rename itself Avenzo Therapeutics, Inc. and trade on the Nasdaq Capital Market under the symbol "AVZO" with new CUSIP number 053928 107.
- Par value and authorized shares unchanged: The par value of $0.0001 per share and the authorized number of shares will remain the same after the split.
- Fractional shares handled in cash: No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment based on the closing price of the common stock on the effective date.
Rallybio Reverse Split Details and Merger Connection
According to the filing, Rallybio Corporation (NASDAQ:RLYB), a Delaware-incorporated emerging growth company headquartered in East Berlin, Connecticut, announced the 1-for-2 reverse stock split in direct connection with the Agreement and Plan of Merger and Reorganization dated May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc., and Farmington Merger Sub, Inc., a wholly owned subsidiary of Rallybio. The reverse stock split is intended to precede the anticipated completion of the merger. Computershare Trust Company, N.A. is acting as the exchange agent and transfer agent for the transaction, the filing disclosed.
The filing stated that at the effective time of the split, every two issued and outstanding shares of common stock will automatically be combined into one share. Proportionate adjustments will be made to the number of shares underlying outstanding pre-funded warrants, equity awards and, where applicable, their exercise prices, as well as to shares reserved under the company's equity incentive plans, in each case in accordance with the terms of the applicable instruments. Stockholders holding shares in book-entry form do not need to take any action, while those holding physical certificates will receive instructions from Computershare.
The filing noted that additional information regarding the reverse stock split is available in the company's proxy statement/prospectus, included in its registration statement on Form S-4, which the Securities and Exchange Commission declared effective on October 15, 2026. The filing also contained forward-looking statements regarding the merger's timing and completion, which the company cautioned are subject to risks including the possibility that the merger could be delayed or not completed if closing conditions, including Nasdaq listing approvals, are not satisfied or waived.
What Was Disclosed
Rallybio's 8-K, filed November 10, 2026, disclosed a board-approved 1-for-2 reverse stock split effective November 20, 2026, reducing outstanding shares from approximately 5.6 million to approximately 2.8 million, with a planned post-merger name change to Avenzo Therapeutics, Inc. and new ticker "AVZO."



Please wait processing your request...